Insulin-like growth factor II
Also known as: IGF-2, IGF-II, IGF2, Multiplication-stimulating activity (MSA), Somatomedin A
Source Insulin-like growth factor II at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Insulin-like growth factor II (IGF‑II) is a naturally occurring peptide hormone that promotes cell proliferation and fetal growth. It is studied primarily in research settings for its role in adrenal cancers, placental development, and neurodegenerative processes. IGF‑II circulates bound to soluble IGF‑II/M6P receptors and can act through membrane‑bound IGF‑II/M6P receptors to influence intracellular signaling pathways.
Mechanism of Action
IGF‑II binds the cation‑independent mannose‑6‑phosphate/IGF‑II receptor (IGF‑II/M6P or IGF2R), a single‑pass transmembrane glycoprotein that mediates clearance of excess IGF‑II and initiates intracellular signaling cascades implicated in growth, neurotransmitter release, and memory consolidation. The receptor also traffics lysosomal enzymes and can modulate amyloid precursor protein processing, linking IGF‑II activity to neurodegenerative pathways.
What the Research Shows
Observational studies of adrenal tumors report that malignant adrenocortical lesions frequently overexpress IGF‑II, suggesting a role in tumor pathogenesis (Curr Opin Oncol 2002). In adrenocortical carcinoma, IGF‑II overexpression is a common molecular alteration, and novel therapies targeting the IGF‑I receptor are under investigation (Horm Res 2009). Neurobiology research highlights that IGF‑II/M6P receptor overexpression can affect amyloid precursor protein processing and β‑amyloid generation, implicating IGF‑II in Alzheimer disease mechanisms (Mol Neurobiol 2017). Soluble circulating IGF‑II/M6P receptor acts as an IGF‑II carrier and antagonist, correlating with fetal growth parameters and rising in certain liver and tumor diseases (Best Pract Res Clin Endocrinol Metab 2015). Finally, increasing IGF‑II availability is proposed as a therapeutic strategy for placental dysfunction, though this remains pre‑clinical (J Endocrinol 2017).
Reported Benefits
Research suggests IGF‑II may support fetal growth, as indicated by correlations between soluble receptor ratios and birth weight. Its involvement in tumor biology provides a potential biomarker for aggressive adrenal cancers. Modulating IGF‑II signaling could influence neurodegenerative pathways, offering a conceptual target for Alzheimer disease. Enhancing IGF‑II availability is being explored to improve uteroplacental blood flow in pre‑eclampsia and fetal growth restriction.
Limitations of the Evidence
Evidence for IGF‑II’s therapeutic utility is largely pre‑clinical or observational; no clinical trials have tested IGF‑II itself as a treatment. The relationship between IGF‑II overexpression and malignancy is correlative, and causality remains unproven. Neurodegenerative findings are based on in‑vitro and animal models, requiring validation in humans. The soluble receptor’s role as a disease marker is still speculative, and its measurement is not standardized.
Safety Considerations
The abstracts do not report specific adverse events for administered IGF‑II. However, overexpression of IGF‑II is linked to malignant adrenal tumors, raising theoretical concerns that exogenous IGF‑II could promote unwanted cell proliferation. Caution is warranted in contexts where tumor growth is a risk. No dosing or toxicity data are available from the cited literature.
How It Is Administered
IGF‑II is studied for administration by intravenous or subcutaneous injection in research protocols. Formulations are not described in the cited abstracts, and the compound remains investigational without approved therapeutic products.
Routes of Administration
Goals & Uses
- Stimulate cellular growthResearchHigh
- Metabolic regulation / insulin sensitizationMetabolismLow
- Neuroprotection and cognitive functionNeurologyLow
- Oncology biomarker / cancer driver understandingOncology / ResearchModerate
- Fetal and neonatal growth supportEndocrinology / GrowthLow
- Muscle regeneration and repairMusculoskeletalLow
- Fetal development studiesResearchHigh
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Diabetic retinopathyOphthalmologyModerate
- Acromegaly or gigantismEndocrineHigh
- Hypoglycemia risk / insulin-secreting tumorsEndocrinologyHigh
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- HypoglycemiaMetabolicUnknownAbnormally low blood glucose
- Injection site reactionsLocalCommon
- Tumor growth promotionOncologyUnknown
- Headache and intracranial hypertensionNeurologicalUncommon
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- Insulin and insulin secretagoguesHigh
- CorticosteroidsModerate
- Anticancer / anti-IGF therapies (e.g., figitumumab, ganitumab)High
- Growth hormoneLow
Population Constraints
- Pediatric patientsAgeRelative
- Patients with Beckwith-Wiedemann syndromeGeneticAbsolute
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
- Patients with personal or family history of cancerOncology RiskRelative
Regulatory Status
- European UnionUnapprovedNot authorized for clinical use.
- United StatesUnapprovedInvestigational research reagent only.
- United KingdomUnapprovedResearch chemical.
Not approved for clinical use in any jurisdiction; investigational only.
Evidence & Sources
- Journal ArticleModerateBertherat J, Mosnier-Pudar H, Bertagna X2002-01-01T00:00:00.000000Z
- Journal ArticleModeratePatalano A, Brancato V, Mantero F2009-01-01T00:00:00.000000Z
- Journal ArticleModerateWang Y, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleModerateScott CD, Kiess W2015-01-01T00:00:00.000000Z
- Journal ArticleModerateSibley CP2017-01-01T00:00:00.000000Z
Frequently Asked Questions
What conditions are associated with abnormal IGF‑II levels?
Elevated IGF‑II expression is observed in malignant adrenocortical tumors and adrenocortical carcinoma, while altered soluble IGF‑II/M6P receptor levels have been linked to fetal growth outcomes, liver cirrhosis, and certain cancers.
Can IGF‑II be used to treat Alzheimer disease?
Current evidence is limited to laboratory studies showing that IGF‑II receptor overexpression influences amyloid precursor protein processing. No clinical data support IGF‑II as a therapy for Alzheimer disease at this time.
Is IGF‑II being investigated for placental disorders?
Yes. Pre‑clinical work proposes increasing IGF‑II availability to improve uteroplacental blood flow and address conditions such as pre‑eclampsia and fetal growth restriction, but human trials have not yet been conducted.
What are the potential risks of giving IGF‑II to patients?
Because IGF‑II can stimulate cell growth, there is a theoretical risk of promoting tumor growth, especially in tissues where IGF‑II is already overexpressed. No specific safety data are available from the cited studies.
How is IGF‑II normally regulated in the body?
IGF‑II circulates bound to soluble IGF‑II/M6P receptors, which can act as antagonists and regulate its bioavailability. The balance between free IGF‑II and receptor binding influences growth processes, particularly during fetal development.
What is Insulin-like growth factor II?
Insulin-like growth factor II (IGF‑II) is a naturally occurring peptide hormone that promotes cell proliferation and fetal growth. It is studied primarily in research settings for its role in adrenal cancers, placental development, and neurodegenerative processes. IGF‑II circulates bound to soluble IGF‑II/M6P receptors and can act through membrane‑bound IGF‑II/M6P receptors to influence intracellular signaling pathways.
What is Insulin-like growth factor II used for?
Insulin-like growth factor II is educationally associated with: Stimulate cellular growth, Metabolic regulation / insulin sensitization, Neuroprotection and cognitive function, Oncology biomarker / cancer driver understanding, Fetal and neonatal growth support, Muscle regeneration and repair, Fetal development studies. Educational only — not medical advice.
How is Insulin-like growth factor II administered?
Recorded routes of administration: Intraperitoneal, Intravenous, Subcutaneous.
What are the potential side effects of Insulin-like growth factor II?
Reported adverse effects include: Edema, Hypoglycemia, Injection site reactions, Tumor growth promotion, Headache and intracranial hypertension. This list is not exhaustive — consult a qualified clinician.
Who should avoid Insulin-like growth factor II?
Recorded contraindications: Active malignancy, Diabetic retinopathy, Acromegaly or gigantism, Hypoglycemia risk / insulin-secreting tumors. Consult a qualified clinician before use.